Parmax Pharma Board Adjourns Q2 Results, Approves Office Shift

Financial Results Status:

The Board meeting agenda for consideration of Un-audited Financial Results for the quarter and half year ended September 30, 2026 was not taken up and approved.
The meeting was adjourned specifically for this agenda item. No new date for considering the financial results was disclosed.

Approved Agenda Items:

1. Shifting of Registered Office:

Approved proposal to shift the company's Registered Office from the State of Gujarat to the State of Maharashtra.
Requires consequent alteration to the Memorandum of Association Clause II from "The Registered office of the Company will be situated in the State of Gujarat" to "The Registered office of the Company is situated in the State of Maharashtra."
Subject to approval of shareholders and other statutory/regulatory approvals under Companies Act, 2013.

2. Enhanced Asset Charge Limits:

Approved enhancing limits under Section 180(1)(a) of Companies Act, 2013 for sale, creation of mortgage or charge on company assets, properties or undertakings.
New limit: ₹50 crores (Rupees Fifty Crores only).
Subject to shareholder approval.

3. Increased Borrowing Limits:

Approved increasing borrowing limits to the Board under Section 180(1)(c) of Companies Act, 2013.
New limit: ₹50 crores (Rupees Fifty Crores only).
Subject to shareholder approval.

4. Internal Auditor Appointment:

Appointed M/s. Bakul V. Ganatra & Co, Chartered Accountants (FRN: 0100915W) as Internal Auditor.
Term: Financial Year 2026-2027.
Appointment date: November 14, 2026.
Firm profile: Based in Rajkot, Gujarat providing services in Direct Taxes, Company Law, Internal Audit and Appellate Advocacy.

5. Variation in Preferential Issue Proceeds:

Approved proposal for variation in terms of utilisation of preferential issue proceeds.
Subject to shareholder approval.